Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation

International Journal of Medical Sciences

Volumn 11, Issue 3, 2014, Pages 268-275

  Gao, Sheng ^a,b   Lin, Bing Yi ^a,b   Yang, Zhe ^a,b,c   Zheng, Zhi Yun ^a,b   Liu, Zhi Kun ^a,b   Wu, Li Ming ^a,b,c   Xie, Hai Yang ^a,b,c   Zhou, Lin ^a,b,c   Zheng, Shu Sen ^a,b,c  

^a BEIJING HOSPITAL   (China)

^b KEY LABORATORY OF ORGAN TRANSPLANTATION   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Metastasis; Metastasis associated in colon cancer 1; Prognosis

Indexed keywords

FOCAL ADHESION KINASE 1; MACC1 PROTEIN, HUMAN; MET PROTEIN, HUMAN; PTK2 PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; ADVERSE EFFECTS; AGED; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893403370     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.7769     Document Type: Article

References (33)

1. Aravalli R. N, Steer C. J, and Cressman E.N. Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008. 48(6): 2047-63.
2. Llovet J. M and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008. 48(4): 1312-27.
3. Parkin D. M, Bray F, Ferlay J, and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): 74-108.
4. Befeler A. S, Hayashi P. H, and Di Bisceglie A.M. Liver transplantation for hepatocellular carcinoma. Gastroenterology, 2005. 128(6): 1752-64.
5. El-Serag H. B, Marrero J. A, Rudolph L, and Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology, 2008. 134(6): 1752-63.
6. Zimmerman M. A, Ghobrial R. M, Tong M. J, Hiatt J. R, Cameron A. M, Hong J, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg, 2008. 143(2): 182-8.
7. Birchmeier C, Birchmeier W, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol, 2003. 4(12): 915-25.
8. Cecchi F, Rabe D. C, and Bottaro D.P. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer, 2010. 46(7): 1260-70.
9. Whittaker S, Marais R, and Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010. 29(36): 4989-5005.
10. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-signaling MET, predicts colon cancer metastasis. Nat Med, 2009. 15(1): 59-67.
11. Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, et al. MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res, 2011. 31(3): 777-80.
12. Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med, 2011. 9: 166.
13. Qu J. H, Chang X. J, Lu Y. Y, Bai W. L, Chen Y, Zhou L, et al. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol, 2012. 18(23): 2995-3003.
14. Wu L. M, Zhang F, Xie H. Y, Xu X, Chen Q. X, Yin S. Y, et al. MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation. Clin Genet, 2008. 73(3): 273-8.
15. Zender L, Villanueva A, Tovar V, Sia D, Chiang D. Y, and Llovet J.M. Cancer gene discovery in hepatocellular carcinoma. J Hepatol, 2010. 52(6): 921-9.
16. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996. 334(11): 693-9.
17. Yao F. Y, Ferrell L, Bass N. M, Watson J. J, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001. 33(6): 1394-403.
18. Zheng S. S, Xu X, Wu J, Chen J, Wang W. L, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008. 85(12): 1726-32.
19. Chiang A. C and Massague J. Molecular basis of metastasis. N Engl J Med, 2008. 359(26): 2814-23.
20. Nguyen D. X and Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet, 2007. 8(5): 341-52.
21. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg, 2011. 141(4): 895-8.
22. Beviglia L and Kramer R.H. HGF induces FAK activation and integrin-mediated adhesion in MTLn3 breast carcinoma cells. Int J Cancer, 1999. 83(5): 640-9.
23. Chen H. C, Chan P. C, Tang M. J, Cheng C. H, and Chang T.J. Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation. J Biol Chem, 1998. 273(40): 25777-82.
24. Matsumoto K, Matsumoto K, Nakamura T, and Kramer R.H. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem, 1994. 269(50): 31807-13.
25. Kaposi-Novak P, Lee J. S, Gomez-Quiroz L, Coulouarn C, Factor V. M, and Thorgeirsson S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest, 2006. 116(6): 1582-95.
26. Park W. S, Dong S. M, Kim S. Y, Na E. Y, Shin M. S, Pi J. H, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res, 1999. 59(2): 307-10.
27. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, and Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology, 1997. 25(3): 619-23.
28. Avizienyte E and Frame M.C. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol, 2005. 17(5): 542-7.
29. Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, et al. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res, 2008. 314(1): 143-52.
30. Kiefel H, Bondong S, Pfeifer M, Schirmer U, Erbe-Hoffmann N, Schafer H, et al. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kappaB activation. Carcinogenesis, 2012. 33(10): 1919-29.
31. Christiansen J. J and Rajasekaran A.K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res, 2006. 66(17): 8319-26.
32. Schmidt C and Marsh J.W. Molecular signature for HCC: role in predicting outcomes after liver transplant and selection for potential adjuvant treatment. Curr Opin Organ Transplant, 2010. 15(3): 277-82.
33. Schwartz M, Dvorchik I, Roayaie S, Fiel M. I, Finkelstein S, Marsh J. W, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol, 2008. 49(4): 581-8.